BMY — Bristol-Myers Squibb Company

The tape is genuinely split, not apathetic. As of 2026-09-13 the stock sits at $63.64, in the top ~8% of its 52-week range ($42.52-$68.64), up 11.4% over three months and 7.7% over six, but it just gave back 4.76% in a single week with RSI at 42.36 - a pullback inside an uptrend, not a breakdown. Fundamentals-based sentiment is constructive: the Q2 2026 print (July 30, 2026) was in line with revenue of $12.97B and $2.04 adjusted EPS, and management raised full-year Eliquis growth guidance to 20-25% from 10-15%; the FDA granted accelerated approval to Zenbexus (iberdomide); arlo-cel produced positive Phase 2 QUINTESSENTIAL topline. The analyst panel is exactly balanced (20 Buy / 20 Hold / 2 Sell) with a $68.29 average target and a $75 high, while bulls point to the new-growth portfolio at ~60% of revenue growing ~14%. The overhang keeping it from Bullish is the 2028 Eliquis loss-of-exclusivity cliff, ~70% U.S. revenue concentration, early-August 2026 AstraZeneca mega-merger speculation (which analysts dismissed as improbable) and ongoing Cytokinetics patent friction.

The trend is an inflection, not a straight line. Revenue YoY went -5.6% (Q1 2025), +0.6% (Q2 2025), +2.8% (Q3 2025), +1.3% (Q4 2025), +2.6% (Q1 2026), +5.7% (Q2 2026) - three consecutive quarters of acceleration and the strongest print in the window. Operating margin has structurally reset upward: 12.9% in Q1 2024 and 21.2% in Q2 2024 versus 31.2%/30.8%/29.8% across Q1-Q3 2025 and 29.3%/31.5% in Q1/Q2 2026. Gross margin followed, from ~55.6% in Q1 2024 to 71.3% in Q2 2026. Net income and EPS confirm it: Q2 2026 net income of $3,317M and diluted EPS of $1.62 versus $1,310M and $0.64 in Q2 2025; H1 2026 EPS of $2.93 versus H1 2025's $1.84. The one genuinely weak leg is cash conversion: TTM operating cash flow is ~$12.8B versus ~$15.9B a year earlier, and Q1/Q2 2026 OCF of $1,104M/$3,393M both fell year over year. Note the base-period distortion - Q1 2024 carried a -$11.9B net loss that gutted stockholders' equity from $29.4B (2023-12-31) to $16.5B (2024-03-31), so any 2024-to-2026 comparison flatters today's numbers. Read plainly: revenue and margin are inflecting, earnings are inflecting, cash flow is not yet.

Cheap on earnings, but it is a patent-cliff discount rather than a mispricing. As of 2026-09-13 the stock trades at 14.0x trailing EPS of $4.55 versus its own 5-year average trailing P/E of 18.21x, and at ~9.2x the $6.93 next-FY consensus EPS - a wider discount to large-cap pharma peers than its 0.23 beta and 4.32% yield would otherwise justify. PEG is 0.17, and price-to-sales of 2.64x is almost exactly the 5-year average of 2.66x, which is why the deterministic overlay labels it 'Neutral vs. its own history' (reference score 64.8) rather than cheap. Price-to-book of 5.82x looks alarming but is largely an artifact of a $22.3B equity base against $42.1B of long-term debt after years of buybacks and acquisition charges - it is a leverage signal, not a growth signal. Net: you are paying roughly 10x forward earnings and ~8.8% trailing free-cash-flow yield for a business with a visible 2028 revenue cliff. That is fair-to-cheap, not expensive.

The market is pricing the cliff, not the current earnings. Trailing EPS of $4.55 and forward EPS of $6.93 mean the forward multiple (9.2x) is far below the trailing one (14.0x) purely because earnings are expected to jump ~52% - so the stock is not 'cheap on earnings that already showed up,' it is cheap on earnings the Street expects but has only partially been delivered. H1 2026 GAAP EPS of $2.93 supports the $6.93 estimate as reachable, but the multiple is the argument: at 9x forward the market is saying it will not pay a normal pharma multiple on 2026 earnings because those earnings sit astride a 2028 step-down. The practical read is that upside re-rating requires either (a) evidence that post-2028 revenue replacement is on track - the ~60%-of-revenue growth portfolio compounding at ~14%, Zenbexus launch, mezigdomide - or (b) a visible path to EPS holding near $6+ through the cliff. If FY2026 lands near $6.93 and the multiple merely holds 10x, the stock is a high-$60s name; if 2027 consensus starts to roll over as Eliquis approaches LOE, the low multiple will prove justified rather than cheap.

As of 2026-09-13, RSI(14) sits at 42.36 - soft but nowhere near oversold, consistent with a cooling pullback inside a rising trend rather than capitulation. The stock is -3.84% below its 20-day SMA (implied ~$66.2), sitting essentially right on its 50-day SMA (+0.34%, implied ~$63.4), and still +8.80% above its 200-day SMA (implied ~$58.5). Momentum is stacked short-term negative / medium-term positive: -4.76% over one week, -0.09% over one month, but +11.40% over three months and +7.72% over six. Practical implication: $63-64 is a decision zone, not a bargain zone - a hold above the 50-day keeps the uptrend intact with the 200-day near $58.5 as the real support shelf if it breaks, while a decisive break below ~$62 would confirm the one-week distribution and put the high-$50s back in play. Chasing here after a -4.8% week with RSI at 42 has no technical edge; waiting for either a 50-day reclaim with volume or a flush toward the 200-day does.

• The 2028 Eliquis loss-of-exclusivity cliff is the dominant macro-sector variable - it suppresses the multiple across the whole large-cap pharma complex and is the reason BMY trades near 9x forward while the sector median sits in the low-to-mid teens.
• U.S. drug-pricing policy and IRA Medicare negotiation: BMY derives roughly 70% of sales domestically, a higher concentration than most peers, so any incremental pricing reform or negotiation list expansion hits it harder than internationally diversified competitors.
• Interest rates and the income trade: a 4.32% dividend yield on a 0.23-beta stock makes BMY a bond proxy for defensive allocators - falling rate expectations support that bid, while higher-for-longer rates make the yield less compelling versus cash and pressure long-duration pharma multiples.
• Sector rotation within healthcare: capital is favoring obesity/immunology growth names, leaving value-oriented large-cap pharma reliant on buybacks, dividends and pipeline news; this caps multiple expansion for BMY regardless of execution.
• Consolidation and litigation climate: early-August 2026 AstraZeneca-BMY deal speculation, generic/biosimilar entry timing, and patent litigation (Cytokinetics) all introduce headline risk that moves the stock independent of quarterly fundamentals.

• Q3 2026 results (expected late October/early November 2026) and whether the upgraded 20-25% Eliquis growth guidance holds and revenue YoY growth extends its acceleration above the +5.7% printed in Q2 2026.
• Zenbexus (iberdomide) U.S. launch trajectory after its accelerated approval, plus the mezigdomide NDA review in multiple myeloma with a PDUFA date of May 13, 2027 - the clearest near-term proof points for the post-2028 revenue-replacement thesis.
• Maturation of the growth portfolio (Camzyos, Breyanzi, Cobenfy and cell therapy) from ~60% of revenue toward the level that can mathematically offset the Eliquis step-down, with deeper arlo-cel and targeted protein degrader datasets at upcoming medical congresses.
• Resolution or escalation of the Cytokinetics patent litigation, and any further patent-cliff or biosimilar timing updates that reset the 2028-2030 revenue bridge.
• Capital allocation signals: continued buyback pace, dividend growth, bolt-on M&A, or renewed AstraZeneca merger chatter - each of which would change how the market capitalizes the depressed multiple.
• Cash-flow normalization: a return of TTM operating cash flow toward the ~$15.9B run-rate of mid-2025 would directly repair the weakest leg of the deterministic score.

• Eliquis concentration risk: the 2028 loss-of-exclusivity and IRA price-negotiation exposure on BMY's largest product is a genuine earnings step-down, not a sentiment issue, and roughly 70% of revenue is U.S.-sourced.
• Deteriorating cash generation against a levered balance sheet: TTM operating cash flow of ~$12.8B is down roughly 20% from ~$15.9B a year earlier, while long-term debt is $42.1B against only $8.7B of cash and $22.3B of equity (D/E 1.93, price-to-book 5.82x). Falling cash flow plus a 4.32% dividend commitment limits flexibility if the cliff deepens.
• Earnings-quality and comparability risk from business development: the -$11.9B Q1 2024 net loss wiped roughly 44% off stockholders' equity in one quarter, showing how quickly a single deal or write-down can distort reported results - and BMY needs more deal-making to replace the cliff.
• P&L and legal overhang: ongoing Cytokinetics patent friction and any adverse ruling on key franchises could accelerate the erosion profile.
• Pipeline execution risk in a crowded multiple-myeloma and CAR-T field, where Zenbexus and arlo-cel must compete against entrenched incumbents to matter financially.
• Valuation-trap dynamic: the 9x forward multiple is only cheap if 2027-2028 estimates hold; if consensus EPS rolls over as the cliff approaches, the multiple compresses further rather than mean-reverting.

BMY is a cheap, defensive, 4.3%-yielding large-cap pharma whose business is measurably improving but whose cash flow and balance sheet are not. The good: revenue growth accelerated for three straight quarters to +5.7% in Q2 2026, operating margin expanded from 12.9% in Q1 2024 to 31.5% in Q2 2026, H1 2026 EPS of $2.93 nearly doubled H1 2025's $1.84, Eliquis guidance was raised, and the stock trades at ~9.2x forward EPS versus its own 18.2x 5-year average trailing P/E with a $68.29 consensus target. The bad: TTM operating cash flow fell ~20% year over year, long-term debt is $42.1B against $22.3B of equity, and the 2028 Eliquis cliff is a real, dated step-down that the market is pricing deliberately rather than irrationally. At $63.64 near the 50-day SMA, this is a fair-to-slightly-cheap stock with a known problem, not a bargain with a hidden one - I would need either a pullback toward the $58-59 200-day area or clearer 2027 EPS visibility before treating the low multiple as free money. This is analysis, not personalized financial advice.

Forward P/E on consensus earnings: I applied a justified multiple of 9.75x to the $6.93 next-FY consensus EPS, giving $67.57. The 9.75x is derived by discounting the stock's own 5-year average trailing P/E of 18.21x and the large-cap pharma forward median (low-to-mid teens) by roughly 25% for the 2028 Eliquis loss-of-exclusivity, ~70% U.S. revenue concentration and IRA negotiation exposure, and it cross-checks against the ~9.9x EV/EBITDA the market currently assigns on $16.5B of trailing EBITDA - i.e. a fair value that is modestly above the 2026-09-13 price of $63.64 but well short of the $75 bull case, because the multiple is only defensible if the growth-portfolio replacement story keeps 2027-2028 estimates intact.